Crescita Therapeutics Inc.
CTX.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 188.82% | -461.28% | 84.77% | -12.25% | -45.75% |
| Total Depreciation and Amortization | 3.70% | -5.64% | 13.94% | 2.97% | -22.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.32% | -225.73% | -52.77% | 51.05% | 208.76% |
| Change in Net Operating Assets | -847.69% | -87.19% | 6.14% | -5.60% | 53.47% |
| Cash from Operations | 99.38% | -136.36% | 216.18% | -22.22% | 42.55% |
| Capital Expenditure | -167.17% | 81.76% | 58.66% | 8.48% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -167.17% | 81.76% | 54.38% | 17.06% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -2.65% | -2.73% | 0.00% | -1.85% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -37.21% | 44.16% | 34.19% | -143.75% | 38.46% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -14.17% | 35.36% | -3.00% | -44.07% | 34.00% |
| Foreign Exchange rate Adjustments | -304.76% | -94.34% | 396.80% | -531.03% | -3.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.03% | -185.85% | 241.75% | -10.94% | -450.23% |